Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galmed Pharmaceuticals Ltd    GLMD   IL0011313900

GALMED PHARMACEUTICALS LTD (GLMD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
15.01(c) 14.68(c) 14.01(c) 15.02(c) 15(c) Last
1 532 798 752 168 539 669 684 911 1 250 427 Volume
-1.51% -2.20% -4.56% +7.21% -0.13% Change
More quotes
Financials (USD)
Sales 2018 0,86 M
EBIT 2018 -11,0 M
Net income 2018 -11,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,87 M
EBIT 2019 -21,9 M
Net income 2019 -21,4 M
Finance 2019 48,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 366x
EV / Sales2019 305x
Capitalization 314 M
More Financials
Company
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company.It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated... 
More about the company
Surperformance© ratings of Galmed Pharmaceuticals Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on GALMED PHARMACEUTICALS LTD
07/13TODAY'S RESEARCH REPORTS ON STOCKS T : Galmed Pharmaceuticals and Zogenix
AC
06/13GALMED PHARMACEUTICALS LTD : Comprehensive Research Report, Galmed Pharmaceutica..
AC
04/16GALMED PHARMACEUTICALS : to Host Post-EASL Key Opinion Leader Call on the Scient..
PU
03/13GALMED PHARMACEUTICALS LTD : Galmed Pharmaceuticals Ltd. to Host Earnings Call
AC
2017GALMED PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Provid..
PU
2017GALMED PHARMACEUTICALS LTD : Galmed Pharmaceuticals Ltd. to Host Earnings Call
AC
2017GALMED PHARMACEUTICALS : Announces Publication of Data on Aramchol™ Mechan..
PU
2017GALMED PHARMACEUTICALS : to Present at International Liver Congress Data that Sh..
PU
2016GALMED PHARMACEUTICALS : and the University of California, San Diego Enter into ..
PU
2016GALMED PHARMACEUTICALS : and SAMIL Pharm Sign a License Agreement for the Commer..
PU
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/20RECAP 7/20 +Pos Comments: $BBD $GLMD $SKX -Neg Comments: $SYK $BBT 
07/20Friday’s Top Analyst Upgrades and Downgrades: $AEP $AXE $CTXS $ETR $ESRX $FB ..
2
07/20SOCIAL ACTIVITY: $GLMD - GALMED PHARMACEUTICALS LTD OR ? TradeIdeas via ?
1
07/20$GLMD initiated at Outperform at Raymond James.
2
07/19$GLMD Setting up to break this descending trend line. 
More tweets
Qtime:52
News from SeekingAlpha
07/20PREMARKET GAINERS AS OF 9 : 05 am (07/20/2018) 
07/20Premarket analyst action - healthcare 
07/15ROUNDS REPORT : Galmed Rallied Subsequent To The Overweight Rating Of Dr. Elemer.. 
07/13Midday Gainers / Losers (07/13/2018) 
07/13HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (7/13/2018) 
Chart GALMED PHARMACEUTICALS LTD
Duration : Period :
Galmed Pharmaceuticals Ltd Technical Analysis Chart | GLMD | IL0011313900 | 4-Traders
Technical analysis trends GALMED PHARMACEUTICALS LTD
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 35,8 $
Spread / Average Target 138%
EPS Revisions
Managers
NameTitle
Allen Baharaff President, Chief Executive Officer & Director
Chaim Hurvitz Chairman
Guy Nehemya Vice President-Operations
Yohai Stenzler Chief Financial Officer
Liat Hayardeny Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALMED PHARMACEUTICALS LTD63.93%314
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC.33.30%9 332